Minimally invasive intra-arterial regional therapy for metastatic melanoma: Isolated limb infusion and percutaneous hepatic perfusion

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 11, 2011, Pages 1383-1394

  Han, Dale ^a   Beasley, Georgia M ^b   Tyler, Douglas S ^b   Zager, Jonathan S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Doxorubicin; ILI; In transit melanoma; Melanoma; Melphalan; Ocular melanoma; Pharmacokinetics; PHP

Indexed keywords

BEVACIZUMAB; BLEOMYCIN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; MELPHALAN; PACLITAXEL; SORAFENIB; TEMOZOLOMIDE;

ALOPECIA; ANEMIA; BONE MARROW TOXICITY; CANCER PATIENT; CARDIOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; ISOLATED LIMB INFUSION; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER TOXICITY; LUNG TOXICITY; MELANOMA; MINIMALLY INVASIVE PROCEDURE; NEUTROPENIA; NONHUMAN; PERCUTANEOUS HEPATIC PERFUSION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SYSTEMIC THERAPY; TECHNIQUE; THROMBOCYTOPENIA; TREATMENT RESPONSE; UVEA MELANOMA;

ADMINISTRATION, CUTANEOUS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; HUMANS; HYPERTHERMIA, INDUCED; LIVER; LIVER NEOPLASMS; MELANOMA; SKIN NEOPLASMS;

EID: 80054761340     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2011.609555     Document Type: Review

References (87)

1. Padsis J, Turley R, Tyler D. Pharmacotherapy of regional melanoma therapy. Expert Opin Pharmacother 2010; 11(1):79-93
2. Gimbel MI, Delman KA, Zager JS. Therapy for unresectable recurrent and in-transit extremity melanoma. Cancer Control 2008;15(3):225-32
3. Alexander HR Jr, Butler CC. Development of isolated hepatic perfusion via the operative and percutaneous techniques for patients with isolated and unresectable liver metastases. Cancer J 2010;16(2):132-41
4. Fraker DL. Hyperthermic regional perfusion for melanoma and sarcoma of the limbs. Curr Probl Surg 1999;36(11):841-907
5. Jaques DP, Coit DG, Brennan MF. Major amputation for advanced malignant melanoma. Surg Gynecol Obstet 1989;169(1):1-6 (Pubitemid 19194324)
6. Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003;44(11):4651-9 (Pubitemid 37315273)
7. Becker JC, Terheyden P, Kampgen E, et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer 2002;87(8):840-5 (Pubitemid 35252958)
8. Rajpal S, Moore R, Karakousis CP. Survival in metastatic ocular melanoma. Cancer 1983;52(2):334-6 (Pubitemid 13063179)
9. Gragoudas ES, Egan KM, Seddon JM, et al. Survival of patients with metastases from uveal melanoma. Ophthalmology 1991;98(3):383-9; discussion 390
10. Seregard S, Kock E. Prognostic indicators following enucleation for posterior uveal melanoma. A multivariate analysis of long-term survival with minimized loss to follow-up. Acta Ophthalmol Scand 1995;p73(4):340-4
11. Kath R, Hayungs J, Bornfeld N, et al. Prognosis and treatment of disseminated uveal melanoma. Cancer 1993;72(7):2219-23 (Pubitemid 23280150)
12. Bedikian AY, Legha SS, Mavligit G, et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 1995;76(9):1665-70
13. Zogakis TG, Bartlett DL, Libutti SK, et al. Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma. Ann Surg Oncol 2001;8(10):771-8 (Pubitemid 34003325)
14. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27(36):6199-206
15. Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer 2007;109(3):455-64 (Pubitemid 46190953)
16. Klaase JM, Kroon BB, van Geel AN, et al. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 1994;115(1):39-45 (Pubitemid 24039210)
17. Minor DR, Allen RE, Alberts D, et al. A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer 1985;55(11):2638-44 (Pubitemid 15092151)
18. Sanki A, Kam PC, Thompson JF. Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology. Ann Surg 2007;245(4):591-6 (Pubitemid 46555663)
19. Kroon HM, Moncrieff M, Kam PC, Thompson JF. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol 2008;15(11):3003-13
20. Beasley GM, Petersen RP, Yoo J, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 2008;15(8):2195-205
21. Sato T. Locoregional management of hepatic metastasis from primary uveal melanoma. Semin Oncol 2010;37(2):127-38
22. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954;30(5):969-77
23. Feldman ED, Pingpank JF, Alexander HR Jr. Regional treatment options for patients with ocular melanoma metastatic to the liver. Ann Surg Oncol 2004;11(3):290-7 (Pubitemid 40486769)
24. Beheshti MV, Denny DF Jr, Glickman MG, et al. Percutaneous isolated liver perfusion for treatment of hepatic malignancy: preliminary report. J Vasc Interv Radiol 1992;3(3):453-8
25. Weinreich DM, Alexander HR. Transarterial perfusion of liver metastases. Semin Oncol 2002;29(2):136-44 (Pubitemid 34297284)
26. Thompson JF, Lai DT, Ingvar C, Kam PC. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res 1994;S1:45-50 (Pubitemid 24144674)
27. Lindner P, Doubrovsky A, Kam PCA, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002;9:127-36 (Pubitemid 34259697)
28. McMahon N, Cheng TY, Beasley GM, et al. Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity? Ann Surg Oncol 2009;16(4):953-61
29. Cheng TY, Grubbs E, Abdel-Wahab O, et al. Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion. Am J Surg 2003;186(5):460-7 (Pubitemid 37352828)
30. Thompson JF, Morton DL, Kroon BBR. editors. Isolated limb perfusion for melanoma: technical aspects. Martin Dunitz; London: 2004. p. 404-9
31. Siemann DW, Chapman M, Beikirch A. Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy. Int J Radiat Biol Relat Stud Phys Chem Med 1991;20:287-9
32. Van der Merwe SA, Van der berg AP, Kroon BB, et al. Modification of human tumour and normal tissue pH during hyperthermic and normothermic antiblastic regional isolation perfusion for malignant melanoma: a pilot study. Int J Hyperthermia 1993;9:205-17 (Pubitemid 23099170)
33. Raymond AK, Beasley GM, Broadwater G, et al. Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Amer Coll Surg 2011;213(2):306-16
34. Fletcher WS, Pommier RF, Small K. Results of cisplatin hyperthermic isolation perfusion for stage IIIA and IIIAB extremity melanoma. Melanoma Res 1994;4(Suppl 1):17-19 (Pubitemid 24144668)
35. Bonenkamp JJ, Thompson JF, de Wilt JH, et al. Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. Eur J Surg Oncol 2004;30(10):1107-12 (Pubitemid 40267817)
36. Hochster H, Strawderman MH, Harris JE, et al. Conventional dose melphalan is inactive in metastatic melanoma: results of an Eastern Cooperative Oncology Group Study. Anticancer Drug Des 1999;10:2r45
37. Parsons PG, Carter FB, Morrison L, Mary SR. Mechanism of melphalan resistance development in human melanoma cell lines. Cancer Res 1981;41:1525-3
38. Grunhagen DJ, deWilt J, Graveland WJ, et al. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer 2006;106:1776-84
39. Grubbs EG, Abdel-Wahab O, Cheng TY, et al. In-transit melanoma: the role of alkylating-agent resistance in regional therapy. J Am Coll Surg 2004;199(3):419-27 (Pubitemid 39120057)
40. Ueno T, Ko SH, Grubbs E, et al. Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. Am J Surg 2004;188(5):532-7 (Pubitemid 39491100)
41. Wieberdink J, Benckhuijsen C, Braat RP. Dosimetry in isolated perfusion of the limbs by assessment of perfused tissue and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905-10 (Pubitemid 13147887)
42. Benckhuijsen C, Kroon BBR, van Geel AN, et al. Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 1988;14:157
43. Wu ZY, Smithers BM, Roberts MS. Tissue and perfusate pharmacokinetics of melphalan in isolated perfused rat hindlimb. J Pharm Exp Ther 1997;282(3):1131-8 (Pubitemid 27408287)
44. Thompson JF, Ramzan I, Kam PCA, et al. Clinical pharmacokinetics of melphalan during isolated limb perfusion: compartmental modeling and moment analysis. Reg Cancer Treat 1995;8:83-7
45. Scott RN, Blackie R, Kerr DJ, et al. Melphalan concentration and distribution in the tissues of tumuor-bearing limbs treated by isolated limb perfusion. Eur J Cancer 1992;11:1811-13
46. Thompson JF, Siebert GA, Anissimov YG, et al. Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies. Br J Cancer 2001;85(2):157-65 (Pubitemid 32700296)
47. Dewhirst MW, Thrall DE, Palmer G, et al. Utility of functional imaging in prediction or assessment of treatment response and prognosis following thermotherapy. Int J Hyperthermia 2010;26(3):283-93
48. Baur A, Stabler A, Wendtner CM, et al. MR-imaging changes of musculoskeletal soft-tissue sarcomas associated with neoadjuvant chemotherapy and hyperthermia. Int J Hyperthermia 2003;19:391-401 (Pubitemid 36798299)
49. Roberts MS, Wu ZY, Siebert GA, et al. Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy. Melanoma Res 2001;11(4):423-31 (Pubitemid 32735234)
50. Santillan AA, Delman KA, Beasley GM, et al. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol 2009;16(9):2570-8
51. Roberts MS, Wu ZY, Siebert GA, et al. Saturable dose-response relationships for melphalan in melanoma treated by isolated limb infusion in the nude rat. Melanoma Res 2001;11(6):611-18 (Pubitemid 33152352)
52. Harada N, Nagasaki A, Hata H, et al. Down-regulation of CD98 in melphalan-resistant myeloma cells with reduced drug uptake. Acta Haematol 2001;103:144-51
53. Grubbs EG, Ueno T, Abdel-Wahab O. Modulation of resistance to regional chemotherapy in the extremity melanoma model. Surgery 2004;136(2):210-18 (Pubitemid 39037656)
54. Eder JP Jr, Chan VT, Ng SW, et al. DNA topoisomerase II alpha expression is associated with alkylating agent resistance. Cancer Res 1995;55:6109-16
55. Komdeur R, Platt BE, Hoekstra HJ, et al. Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Cancer 2001;91(10):1940-8 (Pubitemid 32424122)
56. Clark J, Grabs A, Parsons PG, et al. Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma Melanoma Res. 1994;4:365-70 (Pubitemid 24381889)
57. Abdel-Wahab OI, Grubbs E, Viglianti B. The role of hyperthermia in regional alkylating agent chemotherapy. Clin Cancer Res 2004;10(17):5919-29 (Pubitemid 39180974)
58. Rofstad EK, Mathiesen B. Metastasis in melanoma xenografts is associated with tumor microvascular density rather than extent of hypoxia. Neoplasia 2010;12:889-98
59. Mahabeleshwar GH, Byzova TV. Angiogenesis in melanoma. Semin Oncol 2007;34:555-65 (Pubitemid 350236307)
60. Augustine CK, Yoshimoto Y, Gupta M. Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. Cancer Res 2008;68(10):3777-84
61. Toshimitsu H, Padussis J, Turley R, et al. Targeting N-cadherin to augment the efficacy of regional chemotherapy: a potential double-edged sword? Ann Surg Oncol 2010;17:S1
62. Beasley GM, Riboh J, Augustine CK, et al. Prospective Multicenter Phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. J Clin Oncol 2011; Epub ahead of print
63. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5
64. Senger DR, Perruzzi CA, Feder J, Dvorak HF. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 1986;46:5629-32 (Pubitemid 17177959)
65. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 2006;7:359-71
66. Friedman HS, Prados MA, Wen PY, et al. Bevacizumab Alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-40
67. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42 (Pubitemid 38702844)
68. Dickson PV, Hamner JB, Sims TL, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007;13:3942-50 (Pubitemid 47037602)
69. Turley RS, Padussis JC, Toshimitsu Y, et al. Bevacizumab-induced vascular remodeling augments regional chemotherapy for intransit melanoma. 2011; in preparation
70. Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007;12:426-37 (Pubitemid 46698720)
71. Stein MN, Flaherty KJ. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. Clin Cancer Res 2007;13:3765-70 (Pubitemid 47037579)
72. Wilhelm SM, Carte C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK path-way and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109 (Pubitemid 39331023)
73. Sharma A, Trivedi NR, Zimmerman MA, et al. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 2005;65:2412-21 (Pubitemid 40490153)
74. Augustine CK, Toshimitsu H, Jung SH, et al. Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. Mol Cancer Ther 2010;9(7):2090-101
75. McMahon N, Beasley GM, Sanders G, et al. A phase I study of systemic sorafenib in combination with isolated limb infusion with melphalan (ILI-M) in patients (pts) with locally advanced in-transit melanoma. J Clin Oncol 2009;27(15s):abstract 9065
76. Jilaveanu L, Zito C, Lee SJ, et al. Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. Clin Cancer Res 2009;15:1076-85
77. Cornett WR, McCall LM, Petersen RP, et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006;24(25):4196-201 (Pubitemid 46622299)
78. Sadadcharam M, Soden DC, O'Sullivan GC. Electrochemotherapy: an emerging cancer treatment. Int J Hyperthermia 2008;24(3):263-73 (Pubitemid 351517159)
79. Ramirez LH, Orlowski S, An D, et al. Electrochemotherapy on liver tumors in rabbits. Br J Cancer 1998;77:2104-11
80. Sersa G, Cemazar M, Miklavic D, Chaplin DJ. Tumor blood flow modifying effect of electrochemotherapy with bleomycin. Anticancer Res 1999;19:4017-22
81. Marty MSG, Sersa G, Garbay JR. Electrochemotherapy: an easy highly effective and safe treatment of cutaneous and subcutaneous metastases. Results of ESOPE. Eur J Cancer 2006;4S:3-13
82. Ravikumar TS, Pizzorno G, Bodden W, et al. Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors. J Clin Oncol 1994;12(12):2723-36 (Pubitemid 24379662)
83. Curley SA, Newman RA, Dougherty TB, et al. Complete hepatic venous isolation and extracorporeal chemofiltration as treatment for human hepatocellular carcinoma: a phase I study. Ann Surg Oncol 1994;1(5):389-99
84. Pingpank JF, Libutti SK, Chang R, et al. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol 2005;23(15):3465-74
85. Alexander HR Jr, Libutti SK, Pingpank JF, et al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2003;9(17):6343-9 (Pubitemid 38031818)
86. Pingpank JF, Hughes MS, Alexander HR, et al. A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma. Presented at the American Society of Clinical Oncology, 2010
87. Miao N, Pingpank JF, Alexander HR, et al. Percutaneous hepatic perfusion in patients with metastatic liver cancer: anesthetic, hemodynamic, and metabolic considerations. Ann Surg Oncol 2008;15(3):815-23